SALT LAKE CITY--(BUSINESS WIRE)--Arrien Pharmaceuticals announced today that it has initiated Phase I Clinical trials on their first agent, ARN-6039, which is being developed for the potential treatment of relapse, remitting, and progressive multiple sclerosis (MS), an autoimmune neuroinflammatory demyelinating disease.
Arrien Pharmaceuticals is conducting the Phase I program under an Investigational New Drug (IND) application recently permitted by the FDA. The study is a single-center, randomized, double-blind placebo-controlled safety, tolerability, and pharmacokinetic (PK) study of single ascending oral doses of ARN-6039 in healthy adult subjects.
ARN-6039 is an inverse agonist of ROR-γt that selectively targets the IL-17/TH17 axis and was discovered through Arrien Pharmaceuticals’ fragment-based FIELDS proprietary technology. “We are pleased to broaden Arrien Pharmaceuticals’ pipeline of clinical drug candidates with the advancement of ARN-6039 into clinical Phase I. ARN-6039 is one example of how we have applied our novel platform to create therapeutics that represent new treatment options,” said Hariprasad Vankayalapati, Ph.D., Founder/CSO of Arrien Pharmaceuticals.
“Recent clinical success of IL-17/TH17/ROR targeting agents and oral dosage form, brain-uptake, excellent safety, and efficacy characteristics in models systems, are important aspects of ARN-6039 as potentially innovative new therapy for the treatment of multiple sclerosis,” said John W. Rose, MD, Professor, Chief of Division of Neuroimmunology at University of Utah School of Medicine and SAB member of Arrien Pharmaceuticals.
The progress of ARN-6039 into Phase I development marks the milestone of Arrien Pharmaceuticals into a clinical stage organization. “The exceptional performance of the development team at Arrien Pharmaceuticals has demonstrated the company’s ability to initiate clinical trials for our agent within 16 months of our Series A funding,” said Rajendra P. Appalaneni, Co-founder/Board of Director. “Clearly our focus in the ARN-6039 clinical program will be to provide a meaningful candidate that differentiates current therapeutics for late stage MS patients with this potential first-in-class small molecule.”
The Phase I program planned to enroll 50 healthy human subjects, and we hope to move this program through Phase II proof of efficacy studies in MS patients towards the end of the year. In addition, we will be investigating ARN-6039 in other immune-mediated disorders such as psoriasis in order to fully exploit its therapeutic potential.
About Multiple Sclerosis (MS) and ARN-6039
Multiple sclerosis (MS) is an autoimmune inflammatory demyelinating disease of the CNS (central nervous system) that damages the fatty myelin sheaths around the axons of the brain and spinal cord. This damage and scarring of the myelin sheaths (sclerosis or plaques) results in a broad spectrum of symptoms. Arrien Pharmaceuticals discovered and advanced the development of small molecule inverse-agonist targeting ROR-γt, a key transcription factor and the master regulator of human TH17 (T helper 17) cells. ROR-γt controls cellular differentiation, function, and IL-17 release by TH17 cells and helps mediate the immunopathology of human autoimmune diseases such as multiple sclerosis (MS), psoriasis, rheumatoid arthritis (RA), inflammatory colitis, COPD, and asthma.
About Arrien Pharmaceuticals
Arrien Pharmaceuticals is a small molecule targeted therapeutics drug discovery and development company working towards targeting kinase signaling and nuclear receptor pathways - a target class in treating inflammation, autoimmune, cancer, and neurodegenerative diseases. Arrien Pharmaceuticals successfully applied its proprietary platform FIELDS technology and discovered a pipeline of uniquely positioned pre-clinical stage programs for future treatment of multiple sclerosis (MS), psoriasis, cancer, rheumatoid arthritis (RA), and Parkinson's disease (PD).
For further information on Arrien Pharmaceuticals, please visit the company's website www.arrienpharma.com.
Forward-Looking Statement/Disclaimer:
These materials do not constitute or form part, or all, of any offer or invitation to sell or issue, neither in the United States of America nor elsewhere, or any solicitation of any offer to purchase or subscribe for, any securities, nor shall part, or all, of these materials or their distribution form the basis of, or be relied on in connection with, any contract or investment decision in relation to any securities.
These materials contain forward-looking statements based on the currently held beliefs and assumptions of the management of Arrien Pharmaceuticals, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance, or achievements of Arrien Pharmaceuticals, or industry results, to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements. Given these risks, uncertainties and other factors, recipients of this document are cautioned not to place undue reliance on these forward-looking statements. Arrien Pharmaceuticals disclaims any obligation to update these forward-looking statements to reflect future events or developments.
